Literature DB >> 20308369

Raltegravir penetration in seminal plasma of healthy volunteers.

Andrea Calcagno, Stefano Bonora, Antonio D'Avolio, Marco Siccardi, Marco Simiele, Mattia Chiesa, Daniel Gonzalez de Requena, Giovanni Di Perri.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20308369      PMCID： PMC2876424          DOI： 10.1128/AAC.00241-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  4 in total

Review 1.  Pathophysiology of HIV-1 in semen: current evidence for compartmentalisation and penetration by antiretroviral drugs.

Authors:  Derek J Chan
Journal:  Curr HIV Res       Date:  2005-07       Impact factor: 1.581

2.  High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial.

Authors:  Caroline Barau; Constance Delaugerre; Joséphine Braun; Nathalie de Castro; Valérie Furlan; Isabelle Charreau; Laurence Gérard; Caroline Lascoux-Combe; Jean-Michel Molina; Anne-Marie Taburet
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

3.  An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients.

Authors:  Antonio D'Avolio; Lorena Baietto; Marco Siccardi; Mauro Sciandra; Marco Simiele; Valentina Oddone; Stefano Bonora; Giovanni Di Perri
Journal:  Ther Drug Monit       Date:  2008-12       Impact factor: 3.681

Review 4.  Human immunodeficiency virus viral load in blood plasma and semen: review and implications of empirical findings.

Authors:  Seth C Kalichman; Giorgio Di Berto; Lisa Eaton
Journal:  Sex Transm Dis       Date:  2008-01       Impact factor: 2.830
  4 in total
  7 in total

1.  Detection of Simian Immunodeficiency Virus in Semen, Urethra, and Male Reproductive Organs during Efficient Highly Active Antiretroviral Therapy.

Authors:  G Matusali; N Dereuddre-Bosquet; A Le Tortorec; M Moreau; A-P Satie; D Mahé; P Roumaud; O Bourry; N Sylla; S Bernard-Stoecklin; A Pruvost; R Le Grand; N Dejucq-Rainsford
Journal:  J Virol       Date:  2015-04-01       Impact factor: 5.103

Review 2.  Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention.

Authors:  Christine R Trezza; Angela D M Kashuba
Journal:  Clin Pharmacokinet       Date:  2014-07       Impact factor: 6.447

Review 3.  Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir.

Authors:  Mackenzie L Cottrell; Tanja Hadzic; Angela D M Kashuba
Journal:  Clin Pharmacokinet       Date:  2013-11       Impact factor: 6.447

Review 4.  Antiretroviral bioanalysis methods of tissues and body biofluids.

Authors:  Robin DiFrancesco; Getrude Maduke; Rutva Patel; Charlene R Taylor; Gene D Morse
Journal:  Bioanalysis       Date:  2013-02       Impact factor: 2.681

5.  A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges.

Authors:  Martina Kovarova; Michael D Swanson; Rosa I Sanchez; Caroline E Baker; Justin Steve; Rae Ann Spagnuolo; Bonnie J Howell; Daria J Hazuda; J Victor Garcia
Journal:  J Antimicrob Chemother       Date:  2016-03-21       Impact factor: 5.790

Review 6.  Current perspectives in HIV post-exposure prophylaxis.

Authors:  Binta Sultan; Paul Benn; Laura Waters
Journal:  HIV AIDS (Auckl)       Date:  2014-10-24

7.  HIV-1 RNA may decline more slowly in semen than in blood following initiation of efavirenz-based antiretroviral therapy.

Authors:  Susan M Graham; Sarah E Holte; Joan A Dragavon; Kelly M Ramko; Kishor N Mandaliya; R Scott McClelland; Norbert M Peshu; Eduard J Sanders; John N Krieger; Robert W Coombs
Journal:  PLoS One       Date:  2012-08-13       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.